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The occurrence of multiple cancers in an individual could be due
to: the inheritance of rare genetic mutations which confer a strong
susceptibility to the relevant cancer; inherited mutations in more
common genes, conferring a less pronounced susceptibility;
effects of therapy for the first cancer; misdiagnosed metastases;
environmental exposure increasing the risk of both cancers; or
chance. Several genes in which inherited mutations can predispose
to breast cancer have been identified including BRCA1, BRCA2,
p53 and PTEN. In each case, mutations in the gene increase the
risk of other specific cancers in addition to breast cancer. Co-
occurrence of breast cancer and cancer at another site could be due
to inherited mutations in genes which predispose to both cancer
types. However, this may account for only a small proportion of
cases of multiple cancers. 
In this paper, we have used one of the world’s largest popula-
tion-based cancer registries to identify second cancers which
occur at a higher than expected rate after the diagnosis of female
breast cancer. The sequence of cancers in breast cancer patients
with multiple primaries was also examined. Cases of second
cancer induced by treatment or the misdiagnosis of a metastasis
are clearly sequence-specific, whereas a genetic or environmental
link should not greatly influence the sequence in which the
cancers were diagnosed. Young age at diagnosis is a common
feature of cancer in individuals with a genetic predisposition, and
hence higher risks of a second cancer in younger diagnosed
women than in older diagnosed women could indicate an under-
lying genetic susceptibility. The interval between diagnosis of the
breast cancer and diagnosis of a subsequent cancer can also give
an indication as to whether the association is likely to be treat-
ment related. 
MATERIALS AND METHODS 
The Thames Cancer Registry (TCR) database was used to identify
breast cancer patients with multiple primary cancers. The TCR is a
population-based registry, which collects data on cancer in res-
idents of South East England (a population of 14 million). Data
collection began in 1960 in the South Thames Region and was
extended in 1985 to also cover the North Thames Region. The
patients registered at the TCR represent a cohort of individuals
followed up from diagnosis to death, and the database currently
contains over 1.5 million incident cancers. Approximately 75 000
individuals (5%), identified from the computer system at the TCR,
are diagnosed with multiple tumours (excluding basal cell carci-
nomas of the skin). The numbers of observed second cancers can
be compared with those expected using cancer rates observed in
the corresponding region during the same time period. 
For the analysis of multiple cancers, it is important that meta-
stases or recurrences of the initial tumour should not be misclass-
ified as primary tumours. The rules for accepting a second tumour
as a new primary, rather than a metastasis, are well defined and
nationally agreed among the UK registries. As a general rule, a
new primary tumour needs to be at a different anatomical site and
of a different histological type from the first tumour, or to be stated
explicitly as being a new tumour by the treating clinician. 
An index cohort was created by extracting all registrations
of females with a first breast cancer, resident in the North or
South Thames region, diagnosed between 1 January 1961 and 31
December 1995 from the TCR database. Cases were stratified by
the age at diagnosis of breast cancer (under 50 years or 50 years
and over) and subsequent analyses were performed separately on
these two groups. The cut-off age of 50 years was chosen in order
to include approximately one-quarter of cases in the younger
group (22.5% of breast cancer cases were diagnosed under age
50). Within each individual, subsequent cancers were sequenced
according to the date of diagnosis and the maximum number of
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primary cancers for any one individual was tabulated. For women
diagnosed with two or more cancers subsequent to breast cancer,
each cancer was analysed as an independent observation. 
Non-melanoma skin cancers were excluded, because of known
under-reporting (Scotto et al, 1996). Non-malignant tumours were
also excluded, along with second cancers occurring within one
year of the initial cancer at the same site, with the same laterality
and histology. Patients with a missing date of birth were excluded,
as were cancers without a year of diagnosis or information on resi-
dence of the patient at the time of diagnosis. Patients with two
cancers at different sites diagnosed on the same day were not
included in the analysis. 
In order to identify second cancers that occur at a higher rate
than expected after breast cancer, we computed person years at
risk and applied appropriate population-based rates. For a given
subsequent cancer site, person-years at risk were calculated from
the date of diagnosis of breast cancer to the date of first diagnosis
of cancer at the specified site or to the exit date (date of death, loss
to follow up or 85th birthday, whichever was earlier). Patients
diagnosed prior to 1 January 1971 were followed up actively,
obtaining death information, until 31 December 1982. These
patients were censored at this date. Patients diagnosed after this
date were followed up passively through the NHS Central
Registry, which provides notification of all deaths routinely to the
registry. The follow up of these patients was censored at 31
December 1996. Age/period-specific cancer incidence rates for
the region covered by the TCR were then applied to the cohort, to
calculate the number of subsequent tumours that would be
expected for each site. This number was compared with the
observed number to obtain a standardized incidence ratio (SIR)
estimate and 95% confidence intervals were calculated assuming a
Poisson distribution. Calculations were performed using the statis-
tical package Stata (StataCorp, 1999). A total of 40 cancer sites
were studied, classified according to the 10th revision of the
International Classification of Diseases (ICD) (World Health
Organisation, 1992). No formal correction for multiple testing was
made. 
Further analyses were performed for those second tumour sites
for which more than 100 cases were observed or which showed a
statistically significant association with breast cancer (in either age
group, with either positive or negative association). Each of these
sites was taken as the index tumour, all patients with this tumour
were extracted from the database and their subsequent tumours
tabulated (as above) to estimate whether an excess of breast
cancers was observed. For each site an age cut-off was used to
classify the cases into young age of diagnosis (approximately one
quarter of total cases) or older age of diagnosis. 
The interval between diagnosis of the breast cancer and diag-
nosis of a subsequent cancer was examined to determine if an
association was likely to be due to treatment such as radiotherapy.
SIR estimates for subsequent cancers were calculated for intervals
of 0–4 years, 5–9 years, 10–14 years and more than 15 years after
the breast cancer diagnosis. 
RESULTS 
A total of 145 677 women with breast cancer diagnosed between 1
January 1961 and 31 December 1995 were included in this study,
Table 1 Standardized incidence ratios (SIR) for occurrence of subsequent cancers after initial diagnosis of cancer of the breast (expected number greater than
20 across both age groups, or statistically significant) 
Breast cancer diagnosed at age <50 Breast cancer diagnosed at age 50–84 
Subsequent site n SIR 95% CI n SIR 95% CI 
Tongue 3 1.08 0.35–3.36 13 0.75 0.43–1.28 
Mouth 3 0.96 0.31–2.98 14 0.70 0.41–1.18 
Oesophagus 24 2.39*** 1.60–3.57 143 1.11 0.94–1.30 
Stomach 32 1.83*** 1.29–2.59 257 0.95 0.84–1.07 
Colon 54 0.99 0.76–1.29 517 0.88** 0.80–0.96 
Rectum 27 0.87 0.60–1.27 263 0.91 0.80–1.02 
Liver 0 – – 11 0.39** 0.21–0.70 
Gallbladder 2 0.49 0.12–1.96 40 0.86 0.63–1.17 
Pancreas 24 1.34 0.90–1.99 174 0.78*** 0.67–0.90 
Larynx 3 0.90 0.29–2.79 17 0.81 0.50–1.30 
Lung, bronchus 127 1.49*** 1.26–1.78 526  0.68*** 0.62–0.74 
Bone 4 2.79* 1.05–7.43 3 0.46 0.15–1.44 
Connective tissue 9 2.27* 1.18–4.37 16 0.94 0.58–1.53 
Skin melanoma 32 1.22 0.86–1.72 126 1.19 1.00–1.41 
Breast 768 1.89*** 1.76–2.03 1278 0.88*** 0.83–0.93 
Cervix uteri 31 0.61** 0.43–0.87 103 0.80* 0.66–0.97 
Corpus uteri 67 1.29* 1.02–1.64 429 1.68*** 1.53–1.85 
Ovary 91 1.29* 1.05–1.59 270 0.89 0.79–1.01 
Bladder 19 1.10 0.70–1.72 189 0.94 0.82–1.08 
Kidney 10 0.84 0.45–1.56 80 0.97 0.78–1.21 
Brain/nervous system 14 0.73 0.43–1.24 40  0.59*** 0.43–0.80 
Thyroid 12 1.74 0.99–3.07 25 0.92 0.62–1.36 
NHL 25 0.96 0.65–1.42 127 0.77** 0.65–0.91 
Multiple myeloma 9 1.01 0.52–1.94 55 0.63*** 0.48–0.82 
Lymphoid leukaemia 3 0.57 0.18–1.77 48 0.85 0.64–1.13 
Myeloid leukaemia 22 2.31*** 1.52–3.51 86  1.39** 1.12–1.71 
All sites 1478 1.49*** 1.42–1.57 5038 0.86*** 0.84–0.88 
All sites excluding breast cancer 710 1.21*** 1.13–1.31 3760 0.85*** 0.83–0.88 
n = observed number of cases, * P < 0.05, ** P < 0.01, *** P < 0.001.Breast cancer and multiple primary tumours 437
British Journal of Cancer (2001) 84(3), 435–440 © 2001 Cancer Research Campaign
with a total of 152 453 tumours at all sites fulfilling the criteria for
inclusion. In addition, 551 women had another cancer diagnosed at
a different site on the same day as the breast cancer and were
excluded. 
Patients with breast cancer diagnosis at age less than
50 years. 
A total of 32 799 females were diagnosed with a first breast
tumour under the age of 50 years during the study period. The
mean follow up time was 7.5 years per woman. Multiple tumours
were reported in 1448 (4.4%) cases: 1389 women had two
tumours, 57 had 3 and two women had 4 tumours. 38.6% of subse-
quent tumours were diagnosed within 5 years of the first tumour,
25.6% within 5–9 years, 15.7% within 10–14 years and 20.2%
after at least 15 years. 
The numbers of subsequent tumours observed were more than
expected in 18 of the 40 sites studied. Sites with a number of
expected tumours greater than 20 (across all ages) or with a statisti-
cally significant result (in either age group) are shown in Table 1.
The elevated risk was statistically significant (P < 0.05) in 9 of these
sites: oesophagus (SIR 2.39, 95% CI 1.60–3.57), stomach (SIR
1.83, 95% CI 1.29–2.59), lung (SIR 1.49, 95% CI 1.26–1.78), bone
(SIR 2.79, 95% CI 1.05–7.43), connective tissue (SIR 2.27, 95% CI
1.18–4.37), breast (SIR 1.89, 95% CI 1.76–2.03), corpus uteri (SIR
1.29, 95% CI 1.02–1.64), ovary (SIR 1.29, 95% CI 1.05–1.59) and
myeloid leukaemia (SIR 2.31, 95% CI 1.52–3.51). The increased
risk for a thyroid tumour was of borderline significance (SIR 1.74,
95% CI 0.99–3.07, P= 0.052). A significantly reduced risk was seen
only for cervix uteri (SIR 0.61, 95% CI 0.43–0.87). The overall SIR
for developing a subsequent non-breast cancer after diagnosis of
breast cancer under 50 years of age was 1.21 (95% CI 1.13–1.31). 
The SIR estimates by interval from first diagnosis are shown in
Figure 1, for sites with more than 10 observed tumours and with a
significant association. Cancer of the oesophagus showed a marked
increase at 15 years or more after the breast cancer diagnosis. The
increase in myeloid leukaemia was restricted to the first 5 years after
the breast cancer diagnosis. Risks for other cancer sites were rela-
tively constant, regardless of the time elapsed since the initial cancer. 
Patients with breast cancer diagnosis at age 50 years
and above 
A total of 112 878 females were diagnosed with a first breast
tumour between age 50 and 84 years (77.5% of the total). The mean
follow up time was 5.2 years per person, substantially lower than
the 7.5 years of follow-up for young onset cases. Multiple tumours
were reported in 5034 (4.5%) cases: 4815 women had 2 tumours,
205 had 3 and 14 had 4. 53.8% of subsequent tumours were diag-
nosed within 5 years of the first cancer, 27.4% within 5–9 years,
11.3% within 10–14 years and 7.5% after at least 15 years. 
Of the 40 subsequent tumour sites observed, 8 showed an excess
of observed cancers. Two sites with an expected number of
tumours greater than 20 showed a significant excess: corpus uteri
(SIR 1.68, 95% CI 1.53–1.85) and myeloid leukaemia (SIR 1.39,
95% CI 1.12–1.71). The increase in corpus uteri cancers was seen
in all 4 time intervals after the breast cancer diagnosis, whereas the
rise in myeloid leukaemia was restricted to the first 5 years.
Significantly reduced SIRs were found at 9 sites: colon, liver,
pancreas, lung, breast, cervix uteri, brain, NHL (non- Hodgkin’s
lymphoma) and multiple myeloma. 
Breast cancer as a subsequent tumour 
There was a significant increase in breast cancer after a number of
cancers that were diagnosed at a young age (Table 2): colon (SIR
1.18, 95% CI 1.04–1.43), lung (SIR 1.60, 95% CI 1.23–2.09),
bone (SIR 10.5, 95% CI 1.48–74.4) and thyroid (SIR 1.97, 95% CI
Oesophagus 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Stomach 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Interval (years) Interval (years)
Breast 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Lung, bronchus 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Interval (years) Interval (years)
Corpus uteri 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Ovary 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Interval (years) Interval (years)
Myeloid leukaemia 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Cervix uteri 10
1 
0.1
S
I
R
0–4 5–9 10–14 15+
Interval (years) Interval (years)
Figure 1 Standardized incidence ratios (SIR) for cancers following breast
cancer diagnosed before the age of 50, by interval since diagnosis 
Table 2 Standardized incidence ratios (SIR) for occurrence of breast cancer
after diagnosis of initial cancer at a young age, for sites with more than 10
subsequent breast cancers or showing a statistically significant association 
Age cut-off Observed SIR  95% CI 
(years) number of cases
Oesophagus 65 12 1.36 0.77–2.40 
Stomach 65 22 1.24 0.82–1.89 
Colon 65 150 1.18* 1.04–1.43 
Rectum 60 58 1.18 0.91–1.52 
Lung, bronchus 60 54 1.60*** 1.23–2.09 
Bone 20 1 10.48** 1.48–74.38 
Skin melanoma 40 18 1.12 0.70–1.77 
Cervix uteri 40 28 0.90 0.62–1.30 
Corpus uteri 55 84 0.84 0.68–1.05 
Ovary 55 77 1.12 0.90–1.40 
Bladder 65 73 1.08 0.86–1.35 
Thyroid 40 13 1.97* 1.14–3.39 
NHL 55 18 0.64 0.40–1.02 
Multiple myeloma 65 1 0.09* 0.01–0.61 
* P < 0.05, ** P < 0.01, *** P < 0.001. 1.14–3.39). Significantly fewer breast cancers than expected were
observed after a young diagnosis of multiple myeloma (SIR 0.09,
95% CI 0.01–0.61). 
DISCUSSION 
Comparing women with breast cancer diagnosed under age 50 and
over age 50, we note an increased risk of second cancer occurring
in the younger group. It is difficult to distinguish between cases of
multiple cancers due to a genetic susceptibility and those due to
common environmental factors. However, the majority of associa-
tions were seen with breast cancer diagnosed under age 50, and
early age at onset is considered a hallmark of inherited cancers
(Schottenfeld, 1996). 
It is possible that the overall significant decrease in tumours
reported after an older diagnosis of breast cancer may be due to
under-ascertainment. It is conceivable that medical surveillance is
reduced in older patients. Older women may not have such aggres-
sive treatment as the younger cases and so might develop fewer
treatment-related cancers. 
The common sites of metastasis from breast cancer are bone,
lung, liver and brain. Lung and bone were both significantly over-
represented in the younger age group and it is possible that some
of these were misclassified as primary tumours, but none of these
sites were increased in the older group. 
We would expect tumours induced by therapy for breast cancer
to be over-represented in both groups. Solid tumours resulting
from radiotherapy include cancers of the lung, bone, oesophagus,
thyroid, salivary gland and connective tissue near the irradiation
site. These usually occur 10 or more years after radiation, whereas
leukaemia typically occurs within 5 years of radiotherapy (Boice
et al, 1996). Secondary myeloid leukaemia has also been described
after chemotherapy for breast cancer (Kollmannsberger et al,
1998). 
Myeloid leukaemia was significantly increased within five
years of diagnosis of breast cancer (Figure 1). When the tumour
sequence was reversed, breast cancer was not seen in excess after
diagnosis of myeloid leukaemia. The associations with cancer of
the oesophagus and connective tissue were not seen in the reverse
order, indicating that they may also be due to treatment for breast
cancer. There is evidence that tamoxifen treatment may increase
the risk of cancer of the corpus uteri in some women (Andersson et
al, 1991; Gail et al, 1999), which may account for some of the
excess seen in this study. 
Inherited mutations in genes predisposing for breast cancer
(BRCA1, BRCA2, PTEN, p53) increase risks of other cancers also
and will therefore contribute to the relative risks of subsequent
cancers, particularly for breast cancer diagnosed at a young age
(Ford et al, 1994; Eeles, 1995; Breast Cancer Linkage Consortium,
1999; De Vivo et al, 2000). The penetrance for ovarian cancer in
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Table 3 Summary of relative risks found in other cancer registry studies of multiple cancer following diagnosis of breast cancer 
Area South East England Denmark Connecticut, USA Finland Slovenia 
Reference Current study Ewertz and Mouridsen   Harvey and Brinton Teppo et al  Volk and Pompe-Kirn 
(1985) (1985) (1985) (1997)
Period 1961–1995 1943–1980 1935–1982 1953–1979 1961–1985 
No. of breast cancer cases 32 799 54 964 41 109 26 617 8917 
Age cut-off Under 50y All cases Under 45y All cases All cases 
Subsequent sites (SIR): 
Tongue 1.08 0.7 1.8 NR NR 
Mouth 0.96 1.1 2.2 NR 0.7 
Oesophagus 2.39*** 1.0 1.3 0.78 1.2 
Stomach 1.83*** 1.0 1.1 1.11 0.9 
Colon 0.99 1.1 1.6* 1.36* 1.1 
Rectum 0.87 1.0 1.9* 0.97 1.2 
Liver – 0.7* 1.5 NR 0.7 
Gallbladder 0.49 NR NR 0.43* 0.9 
Pancreas 1.34 1.0 1.8 NR 0.6 
Larynx 0.90 1.0 0.7 NR 3.0 
Lung, bronchus 1.49*** 1.4* 1.7* 1.67** 1.6* 
Bone 2.79* 2.3* 2.6 NR 1.2 
Connective tissue 2.27* 2.1* 1.5 NR 2.0 
Skin melanoma 1.22 1.4* 1.8 NR 2.7* 
Breast 1.89*** NR 5.4* NR 1.4* 
Cervix uteri 0.61** 0.9 1.3 0.95 1.1 
Corpus uteri 1.29* 1.0 1.1 1.33* 1.6* 
Ovary 1.29* 1.3* 2.6* 1.73*** 2.3* 
Bladder 1.10 0.9 0.6 1.65* 1.1 
Kidney 0.84 1.2 0.5 NR 1.0 
Brain/nervous system 0.73 0.8 1.0 NR NR 
Thyroid 1.74 1.1 3.2* 1.95* 2.5* 
NHL 0.96 1.0 1.1 NR 0.9 
Multiple myeloma 1.01 0.7 1.4 NR 0.9 
Lymphoid leukaemia 0.57 1.01 0.01 NR NR 
Myeloid leukaemia 2.31*** 2.52* 2.12 NR NR 
NR = not reported * P<0.05, **P<0.01, ***P<0.001. 1 = chronic lymphocytic leukaemia, 2 = acute nonlymphocytic leukaemia. Denmark, Connecticut and
Slovenia studies stated only P < 0.05. Breast cancer and multiple primary tumours 439
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BRCA1 mutation carriers is approximately 0.6 (Easton et al, 1995),
compared to the lifetime population risk of 0.013 (RR = 46.15). If
we assume that 3% of breast cancer cases diagnosed under age 50
are  BRCA1 mutation carriers (Peto et al, 1999) and that the
remaining cases have the population risk for ovarian cancer, then
the predicted SIR for ovarian cancer subsequent to breast cancer
would be 2.35, which is higher than our estimate of 1.29 (95% CI
1.05–1.59). These calculations are approximations, and ignore the
effect of ovarian cancer in BRCA2 mutation carriers, or possibly
lower survival rates for breast cancer cases, but they suggest that
mutations in BRCA1 and  BRCA2 could fully account for the
observed increased risk of ovarian cancer following breast cancer. 
In our study, thyroid cancer risks are increased after breast cancer
diagnosed under age 50 (SIR 1.74). However, the increase is
unlikely to be due to radiotherapy for breast cancer, since the risk of
breast cancer is also significantly increased after thyroid cancer
diagnosed under age 40 (SIR 1.97). This supports findings reported
previously (Ron et al, 1984; Vassilopoulou-Sellin et al, 1999).
Genetic syndromes associated with a predisposition to thyroid
cancer include Cowden disease (Liaw et al, 1997); ataxia telangiec-
tasia (Swift et al, 1987); inherited multiple endocrine neoplasia type
II (Schimke, 1984); familial adenomatous polyposis (FAP) and
hereditary non-polyposis colorectal cancer (HNPCC) (Houlston
and Stratton, 1995). However, few of these are considered to be an
important cause of breast cancer (Warren et al, 1992; Fitzgerald et
al, 1997; Freihoff et al, 1999; Inskip et al, 1999). 
Stomach cancer is associated with BRCA2 mutations as well as
a number of other genetic syndromes (FAP, HNPCC, Peutz-
Jegher’s syndrome and Cowden disease), but these are rare and it
is unlikely that they can explain the excess risk associated with
breast cancer (Bevan and Houlston, 1999). A Swedish study
(Adami et al, 1984) also reported an excess risk of stomach cancer,
which was attributed to the fact that a high proportion of stomach
cancer was diagnosed incidentally at autopsy. 
Some associations found will be due to shared environmental
predisposing factors. Cancers of the breast and the corpus uteri
share common reproductive risk factors such as nulliparity, early
menarche and late onset of menopause. The lack of an increased
risk of breast cancer after cancer of the corpus uteri could be
explained by the fact that treatment for cancer of the corpus uteri
may include removal of the ovaries, which would decrease the
subsequent breast cancer risk (Henderson et al, 1996). This is also
true for breast cancer occurring after ovarian cancer. Similarly, the
risk of a second breast cancer reported in this study is likely to be
lower than the true risk as it does not account for the fact that a
proportion of women will have had mastectomies. There were
significantly fewer than expected cases of cervical cancer after
breast cancer, and of breast cancer after cervical cancer. A small
deficit of cervical cancer cases following breast cancer was seen in
a study from the Birmingham Regional Cancer Registry (Prior and
Waterhouse, 1981), and Peto et al (1996) found decreased
mortality rates from cervical cancer in first degree relatives of
breast cancer cases. 
The increased risk for lung cancer after breast cancer observed
in this study has been reported by other cancer registry studies.
However, the reasons for the association have not been fully
explained. Smoking is not thought to be a risk factor for breast
cancer (Palmer and Rosenberg, 1993). Radiotherapy may account
for some of the association, although a Connecticut study (Harvey
and Brinton, 1985) reported an increase in women who did not
have radiotherapy as well as in those that did. 
Other cancer registries have reported similar studies of women
with breast cancer, four of which are summarized in Table 3. At
least 3 of the 4 report increased risks for cancers of the lung,
corpus uteri, ovary and thyroid, as reported in our study. 
We have identified several sites for which women diagnosed
with breast cancer are at higher risk of developing cancer.
Associations with some sites could be due to known genes (ovary),
shared environmental factors (corpus uteri), or the effects of
therapy (myeloid leukaemia). Other associations, such as thyroid
and stomach, are more difficult to explain. They may be artefac-
tual, or they could be caused by more common but less penetrant
genetic mutations causing only a moderately raised susceptibility
to these cancers. 
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